Baxter International (NYSE:BAX) Posts Quarterly Earnings Results, Beats Estimates By $0.05 EPS

Baxter International (NYSE:BAX) released its quarterly earnings results on Thursday. The medical instruments supplier reported $0.36 earnings per share for the quarter, beating analysts’ consensus estimates of $0.31 by $0.05, FiscalAI reports. The company had revenue of $2.70 billion during the quarter, compared to the consensus estimate of $2.62 billion. Baxter International had a negative net margin of 8.51% and a positive return on equity of 16.95%. The firm’s quarterly revenue was up 2.9% on a year-over-year basis. During the same period in the previous year, the business earned $0.62 earnings per share.

Here are the key takeaways from Baxter International’s conference call:

• Reported Q1 sales were $2.7B (+3% reported, -1% organic) and adjusted EPS fell to $0.36 from $0.55, and management is reiterating full-year guidance of $1.85–$2.05 on flat to +1% reported sales.
• The Novum LVP infusion pump remains on a ship-and-installation hold; hardware/software fixes are being finalized and may require regulatory submissions, and the company continues to factor potential customer returns into its guidance despite returns being immaterial in Q1.
• Free cash flow turned positive at $76M (vs. -$221M a year ago), and management is prioritizing debt paydown with a target of roughly 3x net leverage by end of 2026, supporting future financial flexibility.
• Management highlighted growth and innovation tailwinds — Advanced Surgery grew 10% and new product launches (Connex 360, Dynamo stretcher, IV Verify Line Labeling, XR Spine) plus Connected Care/AI initiatives are cited as drivers for back‑half improvement.
• The company reiterated a full-year adjusted operating margin target of 13%–14%, expects ~500 bps of margin expansion in H2 (volume ~250 bps, cost actions ~125 bps, inventory roll-through ~125 bps), and estimates tariffs will be an ~$80M headwind for the year.

Baxter International Price Performance

BAX stock traded up $0.71 during trading on Thursday, reaching $17.61. 21,191,962 shares of the company were exchanged, compared to its average volume of 6,524,775. The company has a 50-day moving average of $17.92 and a two-hundred day moving average of $19.18. The company has a market capitalization of $9.09 billion, a price-to-earnings ratio of -9.52, a P/E/G ratio of 1.20 and a beta of 0.62. Baxter International has a twelve month low of $15.73 and a twelve month high of $32.68. The company has a debt-to-equity ratio of 1.55, a current ratio of 2.31 and a quick ratio of 1.56.

Baxter International Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, April 1st. Investors of record on Friday, February 27th were issued a dividend of $0.01 per share. The ex-dividend date of this dividend was Friday, February 27th. This represents a $0.04 annualized dividend and a dividend yield of 0.2%. Baxter International’s payout ratio is -2.16%.

Trending Headlines about Baxter International

Here are the key news stories impacting Baxter International this week:

• Positive Sentiment: Q1 beat — Baxter reported $0.36 EPS vs. consensus $0.31 and revenue of $2.70B vs. $2.62B, a clear top‑line and headline beat that spurred buying interest. Baxter Reports First-Quarter 2026 Results
• Positive Sentiment: International strength — management and reporters cited robust demand in medical products & therapies and stronger overseas sales as the driver of the beat, supporting revenue momentum outside the U.S. Baxter beats quarterly expectations on strong demand for medical devices
• Positive Sentiment: Management confirms 2026 growth view — company reiterated its growth roadmap and said it is stabilizing the business and improving execution, which reassured investors about forward plans. Baxter Posts 1Q Loss, Backs 2026 Growth Views
• Positive Sentiment: Sector tailwind and upbeat commentary — healthcare/S&P‑500 index momentum and bullish analyst commentary/forecasts added supportive sentiment around the stock. Baxter Gains Strength Amid S&P 500 Index Healthcare Momentum
• Neutral Sentiment: Earnings call details available — management provided additional color on execution, margins and regional performance on the Q1 call (transcript/slides published), useful for reassessing guidance but no major surprises quoted. Baxter Q1 2026 Earnings Call Transcript
• Negative Sentiment: Margin and profitability pressure — operating margins contracted and net margin remains negative; EPS declined year‑over‑year (from $0.62 a year ago), signaling profit recovery still in progress. BAX Stock Gains on Q1 Earnings & Sales Beat, Margins Contract
• Negative Sentiment: Analyst price target cut — Evercore trimmed its price target for BAX (while keeping an Outperform rating), which could cap near‑term upside despite the beat. Evercore Cuts Baxter (BAX) Price Target, Keeps Outperform Rating

Institutional Trading of Baxter International

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. California State Teachers Retirement System lifted its stake in shares of Baxter International by 2.9% in the 2nd quarter. California State Teachers Retirement System now owns 649,463 shares of the medical instruments supplier’s stock valued at $19,666,000 after acquiring an additional 18,439 shares during the last quarter. United Capital Financial Advisors LLC increased its holdings in Baxter International by 19.2% in the 3rd quarter. United Capital Financial Advisors LLC now owns 10,539 shares of the medical instruments supplier’s stock worth $240,000 after purchasing an additional 1,694 shares in the last quarter. Ameriprise Financial Inc. raised its position in Baxter International by 1.3% in the second quarter. Ameriprise Financial Inc. now owns 7,638,629 shares of the medical instruments supplier’s stock valued at $231,304,000 after purchasing an additional 97,687 shares during the last quarter. Russell Investments Group Ltd. boosted its stake in shares of Baxter International by 35.6% during the fourth quarter. Russell Investments Group Ltd. now owns 3,410,689 shares of the medical instruments supplier’s stock valued at $65,216,000 after purchasing an additional 894,761 shares in the last quarter. Finally, Danske Bank A S bought a new stake in shares of Baxter International during the third quarter worth about $5,862,000. Institutional investors own 90.19% of the company’s stock.

Analyst Ratings Changes

BAX has been the topic of a number of recent research reports. Evercore lowered their price objective on Baxter International from $23.00 to $22.00 and set an “outperform” rating on the stock in a research note on Monday, April 6th. Jefferies Financial Group cut their target price on Baxter International from $21.00 to $19.00 and set a “hold” rating for the company in a research report on Friday, February 13th. Zacks Research lowered Baxter International from a “hold” rating to a “strong sell” rating in a report on Friday, April 24th. The Goldman Sachs Group dropped their price target on Baxter International from $21.00 to $17.00 and set a “neutral” rating for the company in a research note on Friday, February 13th. Finally, Wall Street Zen cut shares of Baxter International from a “buy” rating to a “hold” rating in a research report on Saturday, February 7th. Two investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Reduce” and a consensus price target of $19.80.

Baxter International Company Profile

Baxter International Inc is a global healthcare company that develops, manufactures and markets a broad portfolio of medical products, pharmaceutical therapies and biotechnology-based solutions. The company’s primary business activities are organized around renal care, medication delivery, acute therapies, pharmacy automation, surgical care and biotechnology. Baxter’s offerings are designed to support patient care in hospitals, dialysis centers, nursing homes and other healthcare facilities worldwide.

In the renal care segment, Baxter provides hemodialysis and peritoneal dialysis systems, water treatment equipment and related disposables, including dialyzers, bloodlines and catheters.